Biotech | pharmaphorum

Saturday 19 September 2026

Biotech

News

Insilico ends 2025 with $293m Hong Kong IPO

Insilico ends 2025 with $293m Hong Kong IPO

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.

Digital

Cracking the code: How European biotechs can win in the US market

Cracking the code: How European biotechs can win in the US m...

At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for emerging pharma and biotech...

R&D

Businessman looking at cityscape

Future glances: More change, more tech, more harmonisation

According to Deloitte’s 2026 Life Sciences Outlook Survey, the life sciences sector might be becoming increasingly borderless, but only 41% of responding biopharma and medtech executives fe

R&D

Cells under microscope

Why drug delivery is biotech’s overlooked challenge – and it...

Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.

News

Protego's $130m for amyloidosis drug, and other financings

Protego's $130m for amyloidosis drug, and other financings

Our latest crop of biotech financings has nine-figure rounds for Protego and Triana, with Excelsior Sciences and SciNeuro also raising new funds.

News

Veraxa says delayed US listing is back on track

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.